Publications by authors named "Remy Delva"

Claim this Profile
T
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.
Karim Fizazi, Johann S de Bono, A Douglas Laird, Philippe Barthélémy, Rémy Delva

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
Shanna Rajpar, Tony Ibrahim, Alexandra Carmel, Zahira Merabet, Philippe Vielh, Rémy Delva

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.
Soufyan Annakib, Emma Di Méglio, Yona Dibert-Bekoy, Thierry Chevallier, Guilhem Roubaud, Remy Delva

Cancer Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, Lance Pagliaro, Josef Mardiak, Remy Delva

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Valentina Orlando, Damien Drubay, Pernelle Lavaud, Laura Faivre, François Lesaunier, Remy Delva

Clin Genitourin Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study).
Cassandre Gluszak, Manon de Vries-Brilland, Valérie Seegers, Céline Baroin, Helene Kieffer, Remy Delva

Oncologist· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc

Eur Urol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, Rémy Delva

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis

Cancer Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Sotheara Moeung, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, Rémy Delva

Pharm Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Eric Voog, Boris Campillo-Gimenez, Claude Elkouri, Franck Priou, Frederic Rolland, Remy Delva

Int J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Xavier Grimaux, Rémy Delva, Eric Jadaud, Anne Croue

Australas J Dermatol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Stéphane Oudard, Igor Latorzeff, Armelle Caty, Laurent Miglianico, Emmanuel Sevin, Remy Delva

JAMA Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.
Sotheara Moeung, Christine Chevreau, Vianney Poinsignon, Jérôme Guitton, Bénédicte Lelièvre, Rémy Delva

Ther Drug Monit· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gwenaëlle Gravis, Emilien Billon, Capucine Baldini, Christophe Massard, Werner Hilgers, Remy Delva

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Pernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, Florence Joly, Stéphane Oudard, Remy Delva

Eur Urol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Sotheara Moeung, Christine Chevreau, Sophie Broutin, Jérôme Guitton, Bénédicte Lelièvre, Rémy Delva

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, Christelle Levy, Alain Lortholary, Rémy Delva

Eur J Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, Michel Soulié, Laurence Albiges, Remy Delva

Eur Urol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Cora Sternberg, Andrew Armstrong, Roberto Pili, Siobhan Ng, Robert Huddart, Rémy Delva

J Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, Florence Joly, Franck Priou, Remy Delva

Eur Urol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Karim Fizazi, Laura Faivre, François Lesaunier, Remy Delva, Gwenaëlle Gravis

Lancet Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Nadine Houédé, Philippe Beuzeboc, Sophie Gourgou, Diego Tosi, Laura Moise, Remy Delva

BMC Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Karim Fizazi, Lance Pagliaro, Agnes Laplanche, Aude Fléchon, Josef Mardiak, Remy Delva

Lancet Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].
Jean-Yves Pierga, Rémy Delva, Xavier Pivot, Marc Espié, Florence Dalenc

Bull Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis